Bilirubin, total

Cholestasis (increased total bilirubin, direct bilirubin, alkaline phosphatase, and y-glutamyl transferase)... 

TC, lamivudine ABC, abacavir APV, amprenavir AST, aspartate aminotransferase ALT, alanine aminotransferase ATV, atazanavir CBC, complete blood cell count D/C, discontinue ddl, didano-sine d4T, stavudine EFV, efavirenz FTC, emtricitabine P1BV, hepatitis B virus F1CV, hepatitis C vims HIV, human immunodeficiency virus IDV, indinavir IV, intravenous LFT, liver function tests LPV/r, lopinavir + ritonavir NNRTI, nonnucleoside reverse transcriptase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NVP, nevirapine PI, protease inhibitor PT, prothrombin time T.bili, total bilirubin TDF, tenofovir disoproxiI fumarate TPV, tipranavir ULN, upper limit of normal ZDV, zidovudine. 

Doxorubicin 3 hours cycles 1 2 and then infused over 1 hour thereafter repeat every 28 days mucositis, alopecia, flushing, shortness of breath, hypotension, headaches, cardiotoxicity, hand-foot syndrome dysfunction. 2. Do not give if total bilirubin is greater than 5 mg/dL. 

Liver Total bilirubin, alkaline phosphatase greater than 2 times upper limit of normal01... 

Total-body irradiation Number of vomiting episodes, nausea by patient self-report, sudden weight changes (SOS), total bilirubin... 

Monitor weight and skin color daily to observe sudden weight changes suggesting SOS. Obtain a total bilirubin determination at least twice weekly or more frequently if SOS is suspected based on weight change. 

Liver function, including AST, ALT, alkaline phosphatase, lactate dehydrogenase (LDH), total and conjugated bilirubin a comprehensive metabolic panel can be ordered (i.e., sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, calcium, AST, ALT, alkaline phosphatase, albumin, and total bilirubin), but phosphorus, magnesium, and fractionated... 

SEM Systolic ejection murmur Tbili Total bilirubin... 

Elevations of alkaline phosphatase, /glutamyl transferase, and total bilirubin in patients with cholestatic illness. 

Patients should have blood urea nitrogen, serum creatinine, aspartate transaminase or alanine transaminase, and a complete blood count determined at baseline and periodically, depending on the presence of other factors that may increase the likelihood of toxicity (advanced age, alcohol abuse, and possibly pregnancy). Hepatotoxicity should be suspected in patients whose transaminases exceed five times the upper limit of normal or whose total bilirubin exceeds 3 mg/dL. At this point, the offending agent(s) should be discontinued, and alternatives selected. 

Current nutritional intake Complete blood cell count Serum electrolytes Sodium Potassium Chloride Bicarbonate Magnesium Phosphorous Calcium Serum glucose Serum albumin Markers for organ function Liver function tests Alkaline phosphatase Aspartate aminotransferase Alanine aminotransferase Total bilirubin Prothrombin time or International normalized ratio Renal function tests Blood urea nitrogen Creatinine Fluid balance Input Oral... 

Total bilirubin—daily in newborns until normal... 

Liver function tests Alkaline phosphatase Aspartate aminotransferase Alanine aminotransferase Total bilirubin Prothrombin time or International normalized ratio (as necessary)... 

Lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase. 

Glucose Lactic dehydrogenase (LDH) Phosphorus Potassium Serum glutamic-oxaloacetic transaminase (SGOT) Serum glutamic-pyruvic transaminase (SGPT) Sodium Total bilirubin Total cholesterol Total protein Triglycerides White cell differential count ... 

With severe hemolysis, more bihrubin is released into the blood than can be transported on albumin and conjugated in the liver. Unconjugated and total bilirubin increase and may produce jaundice and kernicterus. Examples include ... 

F4. Fevery, J., Claes, J., Heirwegh, K., and De Groote, J., Hyperbilirubinaemia significance of the ratio between direct-reacting and total bilirubin. Clin. Chim. Ada 17, 73-79 (1967). 

Premenopausal use There is no indication for premenopausal use of raloxifene. Hepatic function impairment Raloxifene was studied, as a single dose, in Child-Pugh class A patients with cirrhosis and serum total bilirubin ranging from 0.6 to 2 mg/dL. Plasma raloxifene concentrations were approximately 2.5 times higher than in controls and correlated with total bilirubin concentrations. Safety and efficacy have not been evaluated further in patients with severe hepatic insufficiency. Carcinogenesis In long term carcinogenicity studies in animals there was an increased incidence of ovarian tumors, testicular interstitial cell tumors, and prostatic adenocarcinomas. 

Experience is limited in patients with ALT more than 10 x ULN. The risk of rechallenge must be considered against demonstrated clinical benefit. Patients with clinical jaundice confirmed by a significant elevation in total bilirubin (more than 3... 

Adverse reactions occurring in 3% or more of patients include fatigue and headache. Lab test abnormalities included the following ALT or AST greater than 5 times the ULN amylase or lipase greater than 2 times the ULN total bilirubin greater than 2.5 g/dL glycosuria hematuria. 

---